LLY

752.43

-0.28%↓

JNJ

177.69

-0.22%↓

ABBV

216.12

-1%↓

UNH

349.05

-1.09%↓

AZN

77.79

-2.2%↓

LLY

752.43

-0.28%↓

JNJ

177.69

-0.22%↓

ABBV

216.12

-1%↓

UNH

349.05

-1.09%↓

AZN

77.79

-2.2%↓

LLY

752.43

-0.28%↓

JNJ

177.69

-0.22%↓

ABBV

216.12

-1%↓

UNH

349.05

-1.09%↓

AZN

77.79

-2.2%↓

LLY

752.43

-0.28%↓

JNJ

177.69

-0.22%↓

ABBV

216.12

-1%↓

UNH

349.05

-1.09%↓

AZN

77.79

-2.2%↓

LLY

752.43

-0.28%↓

JNJ

177.69

-0.22%↓

ABBV

216.12

-1%↓

UNH

349.05

-1.09%↓

AZN

77.79

-2.2%↓

Search

Corvus Pharmaceuticals Inc

Open

5.75 -1.2

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.63

Max

5.82

Belangrijke statistieken

By Trading Economics

Inkomsten

-23M

-8M

Winstmarge

-13,764.773

Werknemers

31

EBITDA

-360K

-10M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+111.49% upside

Dividenden

By Dow Jones

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

107M

440M

Vorige openingsprijs

6.95

Vorige sluitingsprijs

5.75

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 sep 2025, 22:41 UTC

Belangrijke Marktbewegers

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12 sep 2025, 16:04 UTC

Belangrijke Marktbewegers

Upexi Shares Climb on Solana Gains

14 sep 2025, 23:48 UTC

Marktinformatie

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14 sep 2025, 23:41 UTC

Marktinformatie

Gold Edges Lower on Likely Technical Correction -- Market Talk

14 sep 2025, 23:38 UTC

Marktinformatie

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14 sep 2025, 23:13 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 sep 2025, 23:13 UTC

Marktinformatie

Global Energy Roundup: Market Talk

14 sep 2025, 23:13 UTC

Marktinformatie

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14 sep 2025, 23:13 UTC

Marktinformatie

Global Equities Roundup: Market Talk

14 sep 2025, 23:04 UTC

Marktinformatie

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13 sep 2025, 08:20 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

12 sep 2025, 20:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

12 sep 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 sep 2025, 20:09 UTC

Winsten

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12 sep 2025, 19:23 UTC

Marktinformatie

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sep 2025, 19:16 UTC

Marktinformatie

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12 sep 2025, 19:03 UTC

Marktinformatie

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12 sep 2025, 18:59 UTC

Marktinformatie

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12 sep 2025, 18:38 UTC

Marktinformatie
Winsten

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12 sep 2025, 18:33 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12 sep 2025, 18:22 UTC

Marktinformatie

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12 sep 2025, 16:56 UTC

Marktinformatie

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12 sep 2025, 16:22 UTC

Winsten

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12 sep 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 sep 2025, 16:19 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12 sep 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

12 sep 2025, 16:11 UTC

Winsten

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12 sep 2025, 15:37 UTC

Marktinformatie

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12 sep 2025, 15:22 UTC

Marktinformatie

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12 sep 2025, 15:07 UTC

Acquisities, Fusies, Overnames

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

111.49% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 12.33 USD  111.49%

Hoogste 15 USD

Laagste 11 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technische score

By Trading Central

3.165 / 3.5827Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat